ArticleComparative medicine2016
Tranexamic Acid and Supportive Measures to Treat Wasting Marmoset Syndrome.
Article in Comparative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Recent Advances in the Etiology, Diagnosis, and Treatment of Marmoset Wasting Syndrome.Veterinary sciences · 2025Review
- Prevalence of major diseases in common marmosets (Frontiers in veterinary science · 2025Article
- Computational Discovery of AngiomiRs and Evaluating the Synergistic Effects of Target miRNA with Tranexamic Acid in Colorectal Cancer.Current medicinal chemistry · 2025Article
- Review of Environmental and Health Factors Impacting Captive Common Marmoset Welfare in the Biomedical Research Setting.Veterinary sciences · 2023Review
- The Common Marmoset-Biomedical Research Animal Model Applications and Common Spontaneous Diseases.Toxicologic pathology · 2022Article
- Diagnosis and treatment of macrocytic anemia in a perinatal common marmoset: a case report.Laboratory animal research · 2022Article
- Immunohistochemical Characterization of a Duodenal Adenocarcinoma with Pulmonary, Hepatic and Parapatellar Metastases in a Common Marmoset (Callithrixjacchus).Journal of comparative pathology · 2021Article
- Reduced differentiation of intestinal epithelial cells in wasting marmoset syndrome.The Journal of veterinary medical science · 2021Article
- Article
- Measurement of the α1-proteinase inhibitor (α1-antitrypsin) of common marmoset and intestinal protein loss in wasting syndrome.Bioscience reports · 2019Article
- Fecal Concentrations of N-methylhistamine in Common Marmosets (Comparative medicine · 2019Article
- Larger cages with housing unit environment enrichment improve the welfare of marmosets.Experimental animals · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wasting marmoset syndrome (WMS) has high incidence and mortality rates and is one of the most important problems in captive common marmoset (Callithrix jacchus) colonies. Despite several reports on WMS, little information is available regarding its reliable treatment. We previously reported that marmosets with WMS had high serum levels of matrix metalloproteinase 9 (MMP9). MMP9 is thought to be a key enzyme in the pathogenesis of inflammatory bowel disease, the main disease state of WMS, and is activated by plasmin, a fibrinolytic factor. In a previous study, treating mice with an antibody to inhibit plasmin prevented the progression of inflammatory bowel disease. Here we examined the efficacy of tranexamic acid, a commonly used plasmin inhibitor, for the treatment of WMS, with supportive measures including amino acid and iron formulations. Six colony marmosets with WMS received tranexamic acid therapy with supportive measures for 8 wk. The body weight, Hct, and serum albumin levels of these 6 marmosets were increased and serum MMP9 levels decreased after this regimen. Therefore, tranexamic acid therapy may be a new and useful treatment for WMS.
Indexed as
Identifiers
28304250PMC5157962W2913766355What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.